Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (Nasdaq: INBX) is a clinical-stage biopharmaceutical company developing biologic therapeutic candidates using modular protein engineering platforms. Its clinical pipeline focuses on oncology: ozekibart, a tetravalent DR5 agonist being studied in chondrosarcoma, Ewing sarcoma and colorectal… From the company’s description.
Over the twelve months to Jun 30, 2026, Inhibrx Biosciences, Inc. reported a net loss of $138.18M. Operations used $131.89M in cash. In fiscal 2025, it reported revenue of $1.30M, up 550.0% from fiscal 2024, and a net loss of $140.06M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Inhibrx Biosciences, Inc. does
In the company’s own words
Inhibrx Biosciences, Inc. (Nasdaq: INBX) is a clinical-stage biopharmaceutical company developing biologic therapeutic candidates using modular protein engineering platforms. Its clinical pipeline focuses on oncology: ozekibart, a tetravalent DR5 agonist being studied in chondrosarcoma, Ewing sarcoma and colorectal cancer, and INBRX-106, a hexavalent OX40 agonist being evaluated alone and with pembrolizumab in solid tumors, including non-small cell lung cancer and head and neck squamous cell carcinoma. The company’s protein-engineering capabilities include discovery, antibody engineering, translational research, manufacturing development and clinical development. In 2024, following the spin-off and sale of its former parent’s INBRX-101 program to Sanofi, Inhibrx continued as an independent public company with its ongoing programs and discovery pipeline. As of December 31, 2025, its patent estate included 31 solely owned patent families and two co-owned families. Its website is www.inhibrx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- LA JOLLA, CA
- Fiscal year end
- December
- CIK
- 2007919
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Inhibrx Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Inhibrx Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Inhibrx Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Inhibrx Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Inhibrx Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”